Servicio de Endocrinología, Hospital Clínico San Carlos Clínico, Madrid, Spain.
Servicio de Radiodiagnóstico, Hospital Clínico San Carlos Clínico, Madrid, Spain.
Endocrinol Diabetes Nutr (Engl Ed). 2023 Mar;70(3):171-178. doi: 10.1016/j.endien.2023.03.001.
The expanding use of 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) has resulted in an increased frequency of incidentally discovered areas of FDG uptake within the thyroid gland. In these incidentalomas, high malignancy rates are reported. The study aimed, on the one hand, to determine the prevalence in our setting of thyroid incidentalomas in patients with no previous history of thyroid cancer undergoing an FDG PET-CT as well as the risk of malignancy and, on the other hand, to evaluate the usefulness of the maximum standard uptake value (SUVmax) for detecting thyroid cancer.
The FDG PET-CT scans performed at our hospital between June 2013 and December 2020 were retrospectively reviewed. In those incidentalomas with sufficient additional investigation, a diagnosis of benign or malignant was established based on the complementary tests.
From the 21,594 PET-CT scans performed, 398 (1.8%) patients had an incidental FDG uptake, either focal (n=324) or diffuse (n=74). Among incidentalomas with further investigation, the rate of malignancy was higher in patients with focal FDG uptake than in those with diffuse uptake (26.5% versus 4%, respectively, p<0.05). The SUVmax value was significantly lower in benign focal lesions (5.7 [range: 2.3-66] than in malignant ones 10.6 [range: 3.1-51.2]; p<0.05). Nearly a quarter of malignant diagnoses (23.3%) were related to potentially aggressive tumours.
The high rate of malignant tumours found among PET-CT incidentalomas and the high proportion of aggressive tumours demonstrate the need for a standardised approach in the investigation of incidental focal FDG uptake in the thyroid gland.
18F-氟代脱氧葡萄糖(FDG)正电子发射断层扫描-计算机断层扫描(PET-CT)的应用不断扩大,导致甲状腺内偶然发现 FDG 摄取区域的频率增加。在这些偶发瘤中,报道了高恶性肿瘤发生率。该研究一方面旨在确定我们在无甲状腺癌既往病史的患者中进行 FDG PET-CT 检查时甲状腺偶发瘤的患病率,以及恶性肿瘤的风险,另一方面评估最大标准摄取值(SUVmax)检测甲状腺癌的有用性。
回顾性分析了我院 2013 年 6 月至 2020 年 12 月期间进行的 FDG PET-CT 扫描。在那些有足够额外检查的偶发瘤中,根据补充检查结果建立良性或恶性诊断。
在 21594 次 PET-CT 扫描中,398 例(1.8%)患者出现了 FDG 摄取的偶然现象,要么是局灶性(n=324),要么是弥漫性(n=74)。在进一步检查的偶发瘤中,局灶性 FDG 摄取患者的恶性肿瘤发生率高于弥漫性摄取患者(分别为 26.5%和 4%,p<0.05)。良性局灶性病变的 SUVmax 值显著低于恶性病变(分别为 5.7[范围:2.3-66]和 10.6[范围:3.1-51.2];p<0.05)。近四分之一的恶性诊断(23.3%)与潜在侵袭性肿瘤有关。
在 PET-CT 偶发瘤中发现的高恶性肿瘤发生率以及高比例的侵袭性肿瘤表明,在甲状腺局灶性 FDG 摄取的检查中需要采用标准化方法。